The Efficacy of Synchronous Combination of Chemotherapy and EGFR TKIs for the First-Line Treatment of NSCLC: A Systematic Analysis.
<h4>Background</h4>The combination of chemotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) currently has become the hotspot issue in the treatment of non-small lung cancer (NSCLC). This systematic review was conducted to compare the efficacy and safe...
Saved in:
| Main Authors: | Han Yan, Huihui Li, Qin Li, Pengfei Zhao, Wei Wang, Bangwei Cao |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0135829 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Effects of Silibinin Combined With EGFR‐TKIs in the Treatment of NSCLC
by: Xiaocen Wang
Published: (2025-02-01) -
Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC
by: Yingqi Xu, et al.
Published: (2025-12-01) -
Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR‐TKIs Resistance
by: Jin Tian, et al.
Published: (2024-12-01) -
Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC
by: Y. Uehara, et al.
Published: (2024-09-01) -
Prognostic factors influencing overall survival in stage IV EGFR-mutant NSCLC patients treated with EGFR-TKIs
by: Linwu Kuang, et al.
Published: (2025-03-01)